BACKGROUND: Pulmonary hypertension (PH) is among the complications of HIV infection. Combination antiretroviral therapy may influence the progression of HIV-related PH. Because Akt signaling is a potential molecular target of HIV protease inhibitors (HPIs), we hypothesized that these drugs altered monocrotaline- and hypoxia-induced PH in rats by downregulating the Akt pathway, thereby inhibiting pulmonary artery smooth muscle cell proliferation. METHODS AND RESULTS: Daily treatment with each of 3 first-generation HPIs (ritonavir 30 mg/kg, amprenavir 100 mg/kg, and nelfinavir 500 mg/kg) started 3 weeks after a subcutaneous monocrotaline injection (60 mg/kg) substantially diminished pulmonary artery pressure, right ventricular hypertrophy, number of muscularized pulmonary vessels, pulmonary arterial wall thickness, and proliferating pulmonary vascular Ki67-labeled cells without affecting vessel caspase 3 staining. HPI treatment partially prevented the development of hypoxia- and monocrotaline-induced PH. Monocrotaline-induced PH was associated with marked activation of Akt signaling in the lungs and proximal pulmonary arteries, with increases in phosphorylated Akt, phosphorylated glycogen-synthase-kinase-3β (GSK3), and phosphorylated endothelial nitric oxide synthase, all of which decreased markedly after treatment with each HPI. In contrast, PH-associated increases in phosphorylated extracellular signal-related kinase 1/2 and myosin light-chain phosphatase were unaltered by the HPIs. The 3 HPIs and the phosphatidylinositol 3-kinase inhibitor LY294002 inhibited platelet-derived growth factor-induced phosphorylation of Akt and GSK3 in cultured pulmonary artery smooth muscle cells and blocked cell proliferation; this last effect was abolished by the GSK3 inhibitor SB216763. CONCLUSION: These results support an effect of HPIs on pulmonary vascular remodeling mediated by inhibition of Akt phosphorylation and consequently of pulmonary artery smooth muscle cell proliferation.
BACKGROUND: Pulmonary hypertension (PH) is among the complications of HIV infection. Combination antiretroviral therapy may influence the progression of HIV-related PH. Because Akt signaling is a potential molecular target of HIV protease inhibitors (HPIs), we hypothesized that these drugs altered monocrotaline- and hypoxia-induced PH in rats by downregulating the Akt pathway, thereby inhibiting pulmonary artery smooth muscle cell proliferation. METHODS AND RESULTS: Daily treatment with each of 3 first-generation HPIs (ritonavir 30 mg/kg, amprenavir 100 mg/kg, and nelfinavir 500 mg/kg) started 3 weeks after a subcutaneous monocrotaline injection (60 mg/kg) substantially diminished pulmonary artery pressure, right ventricular hypertrophy, number of muscularized pulmonary vessels, pulmonary arterial wall thickness, and proliferating pulmonary vascular Ki67-labeled cells without affecting vessel caspase 3 staining. HPI treatment partially prevented the development of hypoxia- and monocrotaline-induced PH. Monocrotaline-induced PH was associated with marked activation of Akt signaling in the lungs and proximal pulmonary arteries, with increases in phosphorylated Akt, phosphorylated glycogen-synthase-kinase-3β (GSK3), and phosphorylated endothelial nitric oxide synthase, all of which decreased markedly after treatment with each HPI. In contrast, PH-associated increases in phosphorylated extracellular signal-related kinase 1/2 and myosin light-chain phosphatase were unaltered by the HPIs. The 3 HPIs and the phosphatidylinositol 3-kinase inhibitor LY294002 inhibited platelet-derived growth factor-induced phosphorylation of Akt and GSK3 in cultured pulmonary artery smooth muscle cells and blocked cell proliferation; this last effect was abolished by the GSK3 inhibitor SB216763. CONCLUSION: These results support an effect of HPIs on pulmonary vascular remodeling mediated by inhibition of Akt phosphorylation and consequently of pulmonary artery smooth muscle cell proliferation.
Authors: Jean-Philippe Zuber; Alexandra Calmy; John M Evison; Barbara Hasse; Veronique Schiffer; Thomas Wagels; Reto Nuesch; Lorenzo Magenta; Bruno Ledergerber; Rolf Jenni; Rudolf Speich; Milos Opravil Journal: Clin Infect Dis Date: 2004-04-01 Impact factor: 9.079
Authors: Hilario Nunes; Marc Humbert; Olivier Sitbon; Jane H Morse; Zemin Deng; James A Knowles; Catherine Le Gall; Florence Parent; Gilles Garcia; Philippe Hervé; Robyn J Barst; Gérald Simonneau Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Elena A Goncharova; Alaina J Ammit; Carla Irani; Richard G Carroll; Andrew J Eszterhas; Reynold A Panettieri; Vera P Krymskaya Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-08 Impact factor: 5.464
Authors: Chrystelle V Garat; Joseph T Crossno; Timothy M Sullivan; Jane E B Reusch; Dwight J Klemm Journal: J Cardiovasc Pharmacol Date: 2013-12 Impact factor: 3.105
Authors: Amal Houssaini; Marielle Breau; Kanny Kebe; Shariq Abid; Elisabeth Marcos; Larissa Lipskaia; Dominique Rideau; Aurelien Parpaleix; Jin Huang; Valerie Amsellem; Nora Vienney; Pierre Validire; Bernard Maitre; Aya Attwe; Christina Lukas; David Vindrieux; Jorge Boczkowski; Genevieve Derumeaux; Mario Pende; David Bernard; Silke Meiners; Serge Adnot Journal: JCI Insight Date: 2018-02-08
Authors: John P Pribis; Yousef Al-Abed; Huan Yang; Domokos Gero; Hongbo Xu; Marcelo F Montenegro; Eileen M Bauer; Sodam Kim; Sangeeta S Chavan; Changchun Cai; Tunliang Li; Petra Szoleczky; Csaba Szabo; Kevin J Tracey; Timothy R Billiar Journal: Mol Med Date: 2015-09-02 Impact factor: 6.354